MARK SHUKHMAN: Open Payments
NPI 1225087752 · SKOKIE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$18,098 in 50 payments from 14 companies in 2025. Trend: 2023 $60,169 · 2024 $68,400 · 2025 $18,098
Speaker / faculty: $9,700Consulting: $3,520Speaker / faculty: $2,100Food & beverage: $1,968Travel & lodging: $810
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $10,028 |
| ABBVIE INC. | 10 | $4,706 |
| Noven Therapeutics, LLC | 5 | $2,127 |
| Alkermes, Inc. | 4 | $255 |
| Tris Pharma Inc | 2 | $162 |
| Teva Pharmaceuticals USA, Inc. | 1 | $124 |
| E.R. Squibb & Sons, L.L.C. | 1 | $123 |
| Otsuka America Pharmaceutical, Inc. | 1 | $119 |
| Lundbeck LLC | 1 | $113 |
| Neos Therapeutics, LP | 1 | $102 |
Products named: CAPLYTA, VRAYLAR, Xelstrym, REXULTI, Dyanavel XR, ARISTADA, UZEDY, COBENFY.
Industry payments across IL — which companies pay providers there.
